Value would be derived from our revenues from the deals and the potential revenues from indications that we have not partnered for. Only getting a slice of the pie will deter a buyout. I'm glad of that, a buyout is not in the best interests of the shareholders to maximize value.



If Cytodyn had more than one drug in the pipeline, selling off all commercialization rights is not the right strategy. Selling off HIV rights and using some of that revenue to commercialize other indications means increased revenue for us. The increased cash flow can be used to acquire or develop other drugs to continue the company past the point that our exclusive rights to leronlimab expire.